INACTIVATION OF RIBONUCLEOTIDE REDUCTASE IN TUMOR-CELLS AND INHIBITION OF TUMOR-CELL GROWTH BY P-ALKOXYPHENOLS

Citation
U. Wellnitz et al., INACTIVATION OF RIBONUCLEOTIDE REDUCTASE IN TUMOR-CELLS AND INHIBITION OF TUMOR-CELL GROWTH BY P-ALKOXYPHENOLS, Melanoma research, 7(4), 1997, pp. 288-298
Citations number
36
Categorie Soggetti
Medicine, Research & Experimental",Oncology,"Dermatology & Venereal Diseases
Journal title
ISSN journal
09608931
Volume
7
Issue
4
Year of publication
1997
Pages
288 - 298
Database
ISI
SICI code
0960-8931(1997)7:4<288:IORRIT>2.0.ZU;2-C
Abstract
A significant correlation between the inactivation of the growth-regul ating enzyme ribonucleotide reductase (RR) with the growth inhibition of four different tumour cell lines has been found for seven different p-alkoxyphenol derivatives with varying lengths of alkyl side chain. In Novikoff hepatoma and human leukaemia cells, inactivation of RR by p-alkoxyphenols was monitored by electron paramagnetic resonance (EPR) spectroscopy of the catalytically essential tyrosyl radical in the su bunit R2 of RR. A significant inhibition of cellular growth of Novikof f hepatoma cells, human leukaemia cells and two human melanoma cell li nes (MeWo and M5) by p-alkoxyphenols was also observed by growth inhib ition assays, Inactivation of RR in whole tumour cells as well as inhi bition of cellular growth of tumour cell lines by p-alkoxyphenols both show an increase in inhibition with increasing length of the alkyl si de chain; the most effective inhibitors are p-isobutoxyphenol, p-butox yphenol and p-propoxyphenol. The enzyme RR, and in particular the cata lytically essential tyrosyl radical in the active site, is recognized as an important cellular target for growth inhibition of Novikoff hepa toma cells, human leukaemia cells and melanoma cells by p-alkoxyphenol s. Thus, the most potent RR inhibitors p-isobutoxyphenol, p-butoxyphen ol and p-propoxyphenol - may be considered as future antiproliferative drugs for the systemic treatment of melanoma as well as leukaemia and possibly other malignancies.